Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 17, 2021 - Issue 6
Submit an article Journal homepage
14,576
Views
45
CrossRef citations to date
0
Altmetric
Review

A comparative review of immunoassays for COVID-19 detection

Elham Mohita Department of Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, IranCorrespondence[email protected] [email protected]
View further author information
,
Zahra Rostamib School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IranView further author information
&
Hossein Vahidia Department of Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, IranView further author information
Pages 573-599 | Received 26 Oct 2020, Accepted 23 Mar 2021, Published online: 29 Aug 2021

  • Espejo AP, Akgun Y, Al Mana AF, et al. Review of current advances in serologic testing for COVID-19. Am J Clin Pathol. 2020;154(3):293–304.
  • Kubina R, Dziedzic A. Molecularand serological tests for COVID-19 a comparative review of SARS-CoV-2 coronavirus laboratory and point-of-care diagnostics. Diagnostics. 2020;10(6):434.
  • Jamaati H, Dastan F, Tabarsi P, et al. A fourteen-day experience with coronavirus disease 2019 (COVID-19) induced Acute Respiratory Distress Syndrome (ARDS): an Iranian treatment protocol. Iranian Journal of Pharmaceutical Research. 2020;19(1):31–36.
  • Lee CY-P, Lin RT, Renia L, et al. Serological Approaches for COVID-19: epidemiologic perspective on surveillance and control. Front Immunol. 2020;11:879.
  • Dastan F, Saffaei A, Haseli S, et al. Promising Effects of Tocilizumab in COVID-19: a non-controlled, prospective clinical trial. Int Immunopharmacol. 2020;88:106869.
  • Organization WH. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance, 2 March 2020. World Health Organization; 2020.
  • Vengesai A, Midzi H, Kasambala M, et al. A systematic and meta-analysis review on the diagnostic accuracy of antibodies in the serological diagnosis of COVID-19. 2020. DOI: 10.21203/rs.3.rs-34638/v2.
  • Cai XF, Chen J, Hu JL, et al. A peptide-based magnetic chemiluminescence enzyme immunoassay for serological diagnosis of coronavirus disease 2019. J Infect Dis. 2020;222(2):189–195.
  • Wolff F, Dahma H, Duterme C, et al. Monitoring antibody response following SARS-CoV-2 infection: diagnostic efficiency of 4 automated immunoassays. Diagn Microbiol Infect Dis. 2020;98(3):115140.
  • To KKW, Tsang OTY, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study [Article]. Lancet Infect Dis. 2020;20(5):565–574.
  • Wang H, Ai J, Loeffelholz MJ, et al. Meta-analysis of diagnostic performance of serology tests for COVID-19: impact of assay design and post-symptom-onset intervals. Emerg Microbes Infect. 2020;9(1):2200–2211.
  • Lassaunière R, Frische A, Harboe ZB, et al. Evaluation of nine commercial SARS-CoV-2 immunoassays. Medrxiv. 2020. Available from: https://doi.org/10.1101/2020.04.09.20056325
  • GeurtsvanKessel CH, Okba NM, Igloi Z, et al. An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nat Commun. 2020;11(1):1–5.
  • Rastawicki W, Rokosz-Chudziak N. Characteristics and assessment of the usefulness of serological tests in the diagnostic of infections caused by coronavirus SARS-CoV-2 on the basis of available manufacturer’s data and literature review. Przegl Epidem. 2020;74(1):49–68.
  • Ravi N, Cortade DL, Ng E, et al. Diagnostics for SARS-CoV-2 detection: a comprehensive review of the FDA-EUA COVID-19 testing landscape. Biosens Bioelectron. 2020;165:112454.
  • Xu M, Wang D, Wang H, et al. COVID‐19 diagnostic testing: technology perspective. Clin Transl Med. 2020;10(4):e158.
  • Zhou Q, Zhu D, Yan H, et al. A preliminary study on analytical performance of serological assay for SARS-CoV-2 IgM/IgG and application in clinical practice. medRxiv. 2020. Available from: https://doi.org/10.1101/2020.05.05.20092551
  • Yongchen Z, Shen H, Wang X, et al. Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients. Emerg Microbes Infect. 2020;9(1):833–836.
  • Wu J-L, Tseng W-P, Lin C-H, et al. Four point-of-care lateral flow immunoassays for diagnosis of COVID-19 and for assessing dynamics of antibody responses to SARS-CoV-2. J Infect. 2020;81(3):435-442.
  • Pickering S, Betancor G, Galão RP, et al., Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. PLoS Pathog. 2020;16(9): e1008817.
  • Zhao J, Yuan Q, Wang H, et al. Antibody Responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin Infect Dis. 2020;71(16):2027–2034.
  • Ma H, Zeng W, He H, et al. COVID-19 diagnosis and study of serum SARS-CoV-2 specific IgA, IgM and IgG by chemiluminescence immunoanalysis. medRxiv. 2020. Available from: https://doi.org/10.1101/2020.04.17.20064907
  • Saenz-Flor KV, Santafe LM. Concordance of” rapid” serological tests and IgG and IgM chemiluminescence for SARS-COV-2. medRxiv. 2020. Available from: https://doi.org/10.1101/2020.06.01.20114884
  • Perera RA, Mok CK, Tsang OT, et al. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Eurosurveillance. 2020;25(16):2000421.
  • Adams ER, Anand R, Andersson MI, et al. Evaluation of antibody testing for SARS-Cov-2 using ELISA and lateral flow immunoassays. Wellcome Open Res. 2020;5:139..
  • Van Elslande J, Houben E, Depypere M, et al. Diagnostic performance of seven rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients. Clin Microbiol Infect. 2020;26(8):1082–1087.
  • Long Q-X, Liu B-Z, Deng H-J, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;;26(6):845-848.
  • Coste AT, Jaton K, Papadimitriou-Olivgeris M, et al. Comparison of SARS-CoV-2 serological tests with different antigen targets. J Clin Virol. 2021;134:104690.
  • Lou B, Li TD, Zheng SF, et al. Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset. Eur Respir J. 2020;56(2):2000763.
  • Liu W, Liu L, Kou G, et al. Evaluation of nucleocapsid and spike protein-based enzyme-linked immunosorbent assays for detecting antibodies against SARS-CoV-2. J Clin Microbiol. 2020;58(6):e00461-20.
  • Adams ER, Ainsworth M, Anand R, et al. Antibody testing for COVID-19: a report from the national COVID scientific advisory panel. Wellcome Open Research. 2020;5( 139):139.
  • Xia N, Wang G, Gong W. Serological test is an efficient supplement of RNA detection for confirmation of SARS-CoV-2 infection. 2020. DOI:10.20944/preprints202003.0184.v1.
  • Torres R, Rinder HM. Double-edged spike-are SARS-CoV-2 serologic tests safe right now? Lab Med. 2020;51(3):236–238.
  • Wang X, Guo X, Xin Q, et al. Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients. Clin Infect Dis. 2020;71(10):2688-2694.  .
  • Ko J-H, Joo E-J, Park S-J, et al. Neutralizing antibody production in asymptomatic and mild COVID-19 patients, in comparison with pneumonic COVID-19 patients. J Clin Med. 2020;9(7):2268.
  • Zhang P, Gao Q, Wang T, et al. Evaluation of recombinant nucleocapsid and spike proteins for serological diagnosis of novel coronavirus disease 2019 (COVID-19). MedRxiv. 2020. Available from: https://doi.org/10.1101/2020.05.31.20118448.
  • Padoan A, Sciacovelli L, Basso D, et al. IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: a longitudinal study [Article]. Clin Chim Acta. 2020;507:164–166.
  • Brouwer PJM, Caniels TG, Van Der Straten K, et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020;369(6504):643–650.
  • Bonelli F, Sarasini A, Zierold C, et al. Clinical and analytical performance of an automated serological test that identifies S1/S2-Neutralizing IgG in COVID-19 patients semiquantitatively. J Clin Microbiol. 2020;58(9):e01224–20.
  • GeurtsvanKessel CH, Okba NM, Igloi Z, et al. Towards the next phase: evaluation of serological assays for diagnostics and exposure assessment. medRxiv. 2020. Available from: https://doi.org/10.1101/2020.04.23.20077156
  • Burbelo PD, Riedo FX, Morishima C, et al. Sensitivity in detection of antibodies to nucleocapsid and spike proteins of severe acute respiratory syndrome coronavirus 2 in patients with coronavirus disease 2019. J Infect Dis. 2020;222(2):206–213.
  • Schnurra C, Reiners N, Biemann R, et al. Comparison of the diagnostic sensitivity of SARS-CoV-2 nucleoprotein and glycoprotein-based antibody tests. J Clin Virol. 2020;129:104544.
  • Manski CF. Bounding the predictive values of COVID-19 antibody tests. Epidemiology. 2021;32(2):162-167.
  • La Marca A, Capuzzo M, Paglia T, et al. Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays. Reprod Biomed Online. 2020;41(3):483–499.
  • Kumleben N, Bhopal R, Czypionka T, et al. Test, test, test for COVID-19 antibodies: the importance of sensitivity, specificity and predictive powers. Public Health. 2020;185:88–90.
  • Bond K, Nicholson S, Lim SM, et al. Evaluation of Serological Tests for SARS-CoV-2: implications for Serology Testing in a Low-Prevalence Setting. J Infect Dis. 2020;222(8):1280–1288.
  • Wang S, Sakhatskyy P, Chou T-HW, et al. Assays for the assessment of neutralizing antibody activities against Severe Acute Respiratory Syndrome (SARS) associated coronavirus (SCV). J Immunol Methods. 2005;301(1–2):21–30.
  • Kohmer N, Westhaus S, Rühl C, et al. Clinical performance of different SARS-CoV-2 IgG antibody tests. J Med Virol. 2020 Oct;92(10):2243–2247.
  • Algaissi A, Hashem AM. Evaluation of MERS-CoV neutralizing antibodies in sera using live virus microneutralization assay. Methods Mol Biol. 2020;2099:107–116.
  • Amanat F, White KM, Miorin L, et al. An In Vitro Microneutralization Assay for SARS‐CoV‐2 Serology and Drug Screening. Curr Protoc Microbiol. 2020;58(1):e108.
  • Muruato AE, Fontes-Garfias CR, Ren P, et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat Commun. 2020;11(1).
  • Nie J, Li Q, Wu J, et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect. 2020;9(1):680–686.
  • Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol. 2020;38(9):1073–1078.
  • Cinquanta L, Fontana DE, Bizzaro N. Chemiluminescent immunoassay technology: what does it change in autoantibody detection? Autoimmunity Highlights. 2017;8(1):9.
  • Wan Y, Li Z, Wang K, et al. Performance verification of anti-SARS-CoV-2-specific antibody detection by using four chemiluminescence immunoassay systems. Ann Clin Biochem. 2020;57(6):429–434.
  • Russo A, Minichini C, Starace M, et al. Current status of laboratory Diagnosis for COVID-19: a narrative review. Infect Drug Resist. 2020;13:2657.
  • Herroelen PH, Martens GA, De Smet D, et al. Kinetics of the humoral immune response to SARS-CoV-2: comparative analytical performance of seven commercial serology tests. medRxiv. 2020. Available from: https://doi.org/10.1101/2020.06.09.20124719
  • Plebani M, Padoan A, Negrini D, et al. Diagnostic performances and thresholds: the key to harmonization in serological SARS-CoV-2 assays? Clin Chim Acta. 2020;509:1–7.
  • Chew KL, Tan SS, Saw S, et al. Clinical evaluation of serological IgG antibody response on the Abbott Architect for established SARS-CoV-2 infection. Clin Microbiol Infect. 2020;26(9):1256.e9-1256.e11.
  • Bryan A, Pepper G, Wener MH, et al. Performance characteristics of the abbott architect SARS-CoV-2 IgG assay and seroprevalence in Boise, Idaho. J Clin Microbiol. 2020 ;58(8) :e00941-20.
  • Nakano Y, Kurano M, Morita Y, et al. Time course of the sensitivity and specificity of serum anti-SARS-CoV-2 IgM and IgG antibodies for the diagnosis of symptomatic COVID-19 in Japan.Sci Rep. 2021;11(1):2776.
  • Lippi G, Salvagno GL, Pegoraro M, et al. Assessment of Immune Response to SARS-CoV-2 With Fully Automated MAGLUMI 2019-nCoV IgG and IgM Chemiluminescence Immunoassays. Clin Chem Lab Med. 2020;58(7):1156–1159.
  • Favresse J, Eucher C, Elsen M, et al. Clinical Performance of the Elecsys Electrochemiluminescent Immunoassay for the detection of SARS-CoV-2 Total Antibodies. Clin Chem. 2020;66(8):1104–1106.
  • Ong DSY, De Man SJ, Lindeboom FA, et al. Comparison of diagnostic accuracies of rapid serological tests and ELISA to molecular diagnostics in patients with suspected coronavirus disease 2019 presenting to the hospital. Clin Microbiol Infect. 2020;26(8):1094.e7-1094.e10.
  • Marlet J, Petillon C, Ragot E, et al. Clinical performance of four immunoassays for antibodies to SARS-CoV-2, including a prospective analysis for the diagnosis of COVID-19 in a real-life routine care setting. J Clin Virol. 2020;132:104633.
  • Beavis KG, Matushek SM, Abeleda APF, et al. Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies. J Clin Virol. 2020;129:104468.
  • Tuaillon E, Bolloré K, Pisoni A, et al. Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients. J Infect. 2020;81(2):e39–e45.
  • Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020;26(7):1033-1036.
  • Ni L, Ye F, Cheng ML, et al. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals. Immunity. 2020 Jun 16;52(6):971–977.e3.
  • Peterhoff D, Glück V, Vogel M, et al. A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization. Infection. 1–8.
  • Weidner L, Gänsdorfer S, Unterweger S, et al. Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays. J Clin Virol. 2020;129:104540.
  • Patel EU, Bloch EM, Clarke W, et al. Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers. J Clin Microbiol. 2021;59(2):e02257-20.
  • Padoan A, Bonfante F, Pagliari M, et al. Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity. EBioMedicine. 2020;62:103101.
  • Meschi S, Colavita F, Bordi L, et al. Performance evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization test. J Clin Virol. 2020;129:104539.
  • Pflüger LS, Bannasch JH, Brehm TT, et al. Clinical evaluation of five different automated SARS-CoV-2 serology assays in a cohort of hospitalized COVID-19 patients. J Clin Virol. 2020;130:104549.
  • Trabaud MA, Icard V, Milon MP, et al. Comparison of eight commercial, high-throughput, automated or ELISA assays detecting SARS-CoV-2 IgG or total antibody. J Clin Virol. 2020;132:104613.
  • Zhong L, Chuan J, Gong B, et al. Detection of serum IgM and IgG for COVID-19 diagnosis. Sci China Life Sci. 2020 ;63(5):777–780.
  • Lin D, Liu L, Zhang M, et al. Evaluations of the serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak. Eur J Clin Microbiol Infect Dis . 2020;39(12):2271–2277.
  • Egger M, Bundschuh C, Wiesinger K, et al. Comparison of the Elecsys® Anti-SARS-CoV-2 immunoassay with the EDI™ enzyme linked immunosorbent assays for the detection of SARS-CoV-2 antibodies in human plasma. Clin Chim Acta. 2020;509:18–21.
  • Tré-Hardy M, Wilmet A, Beukinga I, et al. Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody. Clin Chem Lab Med. 2020 Jul 28;58(8):1357–1364.
  • Grant BD, Anderson CE, Williford JR, et al. SARS-CoV-2 coronavirus nucleocapsid antigen-detecting half-strip lateral flow assay toward the development of point of care tests using commercially available reagents. Anal Chem. 2020;92(16):11305–11309.
  • Koczula KM, Gallotta A. Lateral flow assays. Essays Biochem. 2016;60(1):111–120.
  • El-Moamly A. Immunochromatographic Techniques: benefits for the diagnosis of parasitic infections. Austin Chromatogr. 2014;1(4):8.
  • Cassaniti I, Novazzi F, Giardina F, et al. Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department. J Med Virol. 2020;92(10):1724–1727.
  • Pan Y, Li X, Yang G, et al. Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients. J Infect. 2020;81(1):e28–e32.
  • Xie J, Ding C, Li J, et al. Characteristics of patients with coronavirus disease (COVID-19) confirmed using an IgM-IgG antibody test. J Med Virol. 2020;92(10):2004–2010.
  • Bond K, Nicholson MS, Hoang MT, et al. Post-market validation of three serological assays for COVID-19. 2020.
  • Prazuck T, Colin M, Giachè S, et al. Evaluation of performance of two SARS-CoV-2 Rapid IgM-IgG combined antibody tests on capillary whole blood samples from the fingertip. PloS One. 2020;15(9):e0237694.
  • Demey B, Daher N, François C, et al. Dynamic profile for the detection of anti-SARS-CoV-2 antibodies using four immunochromatographic assays. J Infect. 2020;81(2):e6–e10.
  • Lee YL, Liao CH, Liu PY, et al. Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patients. J Infect. 2020 ;81(2):e55–e58.
  • Fujigaki H, Takemura M, Osawa M, et al. Reliability of serological tests for COVID-19: comparison of three immunochromatography test kits for SARS-CoV-2 antibodies. Heliyon. 2020;6(9):e04929.
  • Candel FJ, Viñuela-Prieto JM, González Del Castillo J, et al. Utility of lateral flow tests in SARS-CoV-2 infection monitorization. Revista espanola de quimioterapia: publicacion oficial de la Sociedad Espanola de Quimioterapia. 2020;33(4):258–266.
  • Capello F, Cipolla M, Cosco L, et al. The VivaDiag COVID-19 lgM/IgG Rapid Test for the Screening and Early Diagnosis of COVID-19 in patients with No Clinical Signs of the Disease. Int J Endocrinol Metab Disord. 2020;6(1).
  • Liu D, Ju C, Han C, et al. Ultra-sensitive nanozyme-based chemiluminescence paper test for rapid diagnosis of SARS-CoV-2 infection. bioRxiv. 2020. Available from:https://doi.org/10.1101/2020.06.05.131748
  • Bartolini A, Scapaticci M, Bioli M, et al. Immunochromatographic assays for COVID-19 epidemiological screening: our experience. medRxiv. 2020. DOI: 10.1101/2020.05.28.20116046.
  • Imai K, Tabata S, Ikeda M, et al. Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19. J Clin Virol. 2020;128:104393.
  • Spicuzza L, Montineri A, Manuele R, et al. Reliability and usefulness of a rapid IgM-IgG antibody test for the diagnosis of SARS-CoV-2 infection: a preliminary report. J Infect. 2020;81(2):e53–e54.
  • Paiva KJ, Grisson RD, Chan PA, et al. Validation and performance comparison of three SARS-CoV-2 antibody assays. J Med Virol. 2021;93(2):916–923.
  • Whitman JD, Hiatt J, Mowery CT, et al. Test performance evaluation of SARS-CoV-2 serological assays. medRxiv: the preprint server for health sciences. 2020;2020.04.25.20074856.  Available from:http://doi.org/10.1101/2020.04.25.20074856
  • Nicol T, Lefeuvre C, Serri O, et al. Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech). J Clin Virol. 2020;129:104511.
  • Scohy A, Anantharajah A, Bodéus M, et al. Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis. J Clin Virol. 2020;129:104455.
  • Mertens P, De Vos N, Martiny D, et al. Development and potential usefulness of the COVID-19 Ag Respi-Strip diagnostic assay in a pandemic context. Front Med (Lausanne). 2020;7:225.
  • Blairon L, Wilmet A, Beukinga I, et al. Implementation of rapid SARS-CoV-2 antigenic testing in a laboratory without access to molecular methods: experiences of a general hospital. J Clin Virol. 2020;129:104472.
  • Porte L, Legarraga P, Vollrath V, et al. Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples [Article]. Inter J Infect Dis. 2020;99:328–333.
  • Andrey DO, Cohen P, Meyer B, et al. Head-to-head accuracy comparison of three commercial COVID-19 IgM/IgG serology rapid tests. J Clin Med. 2020;9(8):2369.
  • Kruse RL, Huang Y, Smetana H, et al. A rapid, point of care red blood cell agglutination assay for detecting antibodies against SARS-CoV-2. bioRxiv. 2020.
  • Alves D, Curvello R, Henderson E, et al. Rapid Gel Card agglutination assays for serological analysis following SARS-CoV-2 infection in humans. ACS Sens. 2020;5(8):2596–2603.
  • Kontou PI, Braliou GG, Dimou NL, et al. Antibody tests in detecting SARS-CoV-2 infection: a meta-analysis. Diagnostics. 2020;10(5):319.
  • Böger B, Fachi MM, Vilhena RO, et al. Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19. Am J Infect Control. 2021;49(1):21–29.
  • Ghaffari A, Meurant R, Ardakani ACOVID-19. Serological tests: how well do they actually perform? Diagnostics. 2020;10(7):453.
  • Shi J, Han D, Zhang R, et al. Molecular and serological assays for SARS-CoV-2: insights from Genome and Clinical Characteristics. Clin Chem. 2020;66(8):1030–1046.
  • Sood N, Simon P, Ebner P, et al. Seroprevalence of SARS-CoV-2-specific antibodies among adults in Los angeles county, California, on April 10-11, 2020. JAMA. 2020;323(23):2425–2427.
  • Lisboa Bastos M, Tavaziva G, Abidi SK, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ. 2020;370:m2516.
  • Castro R, Luz PM, Wakimoto MD, et al. COVID-19: a meta-analysis of diagnostic test accuracy of commercial assays registered in Brazil. Braz J Infect Dis. 2020;24(2):180–187.
  • Caini S, Bellerba F, Corso F, et al. Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies up to 25 April 2020 and public health implications. Euro Surveill. 2020;25(23):2000980.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.